Thomas Rauch

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

J. Rosenstock, H. Woerle, B. Gallwitz, 2012, The Lancet.

Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β‐hydroxysteroid dehydrogenase‐1 (HSD1) inhibitor in humans: liver and adipose tissue 11β‐HSD1 inhibition after acute and multiple administrations over 2 weeks

T. Heise, H. Woerle, H. Woerle, 2016, Diabetes, obesity & metabolism.

Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus

J. Holst, T. Heise, H. Woerle, 2012, Diabetes Therapy.

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

J. Rosenstock, H. Woerle, B. Gallwitz, 2012, The Lancet.